Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 1/2017

Open Access 01-12-2017 | Review

Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation

Authors: Takashi Tagami, Hideo Yasunaga, Hiroyuki Yokota

Published in: Critical Care | Issue 1/2017

Login to get access

Abstract

This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency medicine 2017. Other selected articles can be found online at http://​ccforum.​com/​series/​annualupdate2017​. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://​www.​springer.​com/​series/​8901.
Literature
1.
Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated out-of-hospital cardiac arrest in Europe. Resuscitation. 2005;67:75–80.CrossRefPubMed
2.
Kitamura T, Iwami T, Kawamura T, et al. Nationwide improvements in survival from out-of-hospital cardiac arrest in Japan. Circulation. 2012;126:2834–43.CrossRefPubMed
3.
4.
Newman M. The chain of survival concept takes hold. JEMS. 1989;14:11–3.
5.
Callaway CW, Soar J, Aibiki M, et al. Part 4: Advanced Life Support: 2015 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations. Circulation. 2015;132:84–S145.CrossRef
6.
Soar J, Nolan JP, Bottiger BW, et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 3. Adult advanced life support. Resuscitation. 2015;95:100–47.CrossRefPubMed
7.
Dorian P, Cass D, Schwartz B, Cooper R, Gelaznikas R, Barr A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N Engl J Med. 2002;346:884–90.CrossRefPubMed
8.
Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016;374:1711–22.CrossRefPubMed
9.
The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 6: advanced cardiovascular life support: section 5: pharmacology I: agents for arrhythmias. Circulation. 2000;102:I112–128.CrossRef
10.
Herlitz J, Ekstrom L, Wennerblom B, et al. Lidocaine in out-of-hospital ventricular fibrillation. Does it improve survival? Resuscitation. 1997;33:199–205.CrossRefPubMed
11.
Harrison EE. Lidocaine in prehospital countershock refractory ventricular fibrillation. Ann Emerg Med. 1981;10:420–3.CrossRefPubMed
12.
Weaver WD, Fahrenbruch CE, Johnson DD, Hallstrom AP, Cobb LA, Copass MK. Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation. Circulation. 1990;82:2027–34.CrossRefPubMed
13.
Kudenchuk PJ, Cobb LA, Copass MK, et al. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999;341:871–8.CrossRefPubMed
14.
15.
Pantazopoulos IN, Troupis GT, Pantazopoulos CN, Xanthos TT. Nifekalant in the treatment of life-threatening ventricular tachyarrhythmias. World J Cardiol. 2011;3:169–76.CrossRefPubMedPubMedCentral
16.
Nakaya H, Tohse N, Takeda Y, Kanno M. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol. 1993;109:157–63.CrossRefPubMedPubMedCentral
17.
Kondoh K, Hashimoto H, Nishiyama H, et al. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol. 1994;23:674–80.CrossRefPubMed
18.
Sen L, Cui G, Sakaguchi Y, Singh BN. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs. J Pharmacol Exp Ther. 1998;285:687–94.PubMed
19.
Murakawa Y, Yamashita T, Kanese Y, Omata M. Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation? J Am Coll Cardiol. 1997;29:688–92.CrossRefPubMed
20.
Tsagalou EP, Anastasiou-Nana MI, Charitos CE, et al. Time course of fibrillation and defibrillation thresholds after an intravenous bolus of amiodarone – an experimental study. Resuscitation. 2004;61:83–9.CrossRefPubMed
21.
Huang J, Skinner JL, Rogers JM, Smith WM, Holman WL, Ideker RE. The effects of acute and chronic amiodarone on activation patterns and defibrillation threshold during ventricular fibrillation in dogs. J Am Coll Cardiol. 2002;40:375–83.CrossRefPubMed
22.
Amino M, Yoshioka K, Opthof T, et al. Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. J Cardiovasc Pharmacol. 2010;55:391–8.CrossRefPubMed
23.
Harayama N, Nihei S, Nagata K, et al. Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. J Anesth. 2014;28:587–92.CrossRefPubMedPubMedCentral
24.
Ji XF, Li CS, Wang S, Yang L, Cong LH. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation. 2010;81:1031–6.CrossRefPubMed
25.
Amino M, Inokuchi S, Nagao K, et al. Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24-hour survival in cardiopulmonary arrest patients: The SOS-KANTO 2012 Study. J Cardiovasc Pharmacol. 2015;66:600–9.CrossRefPubMed
26.
SOS-KANTO 2012 Study group. Changes in pre- and in-hospital management and outcomes for out-of-hospital cardiac arrest between 2002 and 2012 in Kanto, Japan: the SOS-KANTO 2012 Study. Acute Med Surg. 2015;2:225–33.CrossRef
27.
Amino M, Inokuchi S, Yoshioka K, et al. Does antiarrhythmic drug during cardiopulmonary resuscitation improve the one-month survival: The SOS-KANTO 2012 Study. J Cardiovasc Pharmacol. 2016;68:58–66.CrossRefPubMed
28.
Tagami T, Matsui H, Ishinokami S, et al. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. Resuscitation. 2016;109:127–32.CrossRefPubMed
29.
Tagami T, Matsui H, Tanaka C, et al. Amiodarone compared with lidocaine for out-of-hospital cardiac arrest with refractory ventricular fibrillation on hospital arrival: a nationwide database study. Cardiovasc Drugs Ther. 2016;30:485–91.CrossRefPubMed
30.
Tagami T, Matsui H, Fushimi K, Yasunaga H. Changes in therapeutic hypothermia and coronary intervention provision and in-hospital mortality of patients with out-of-hospital cardiac arrest: a nationwide database study. Crit Care Med. 2016;44:488–95.CrossRefPubMed
31.
32.
Amino M, Yoshioka K, Kanda S, et al. Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan. J Arrhyth. 2014;30:180–5.CrossRef
33.
Sanfilippo F, Corredor C, Santonocito C, et al. Amiodarone or lidocaine for cardiac arrest: A systematic review and meta-analysis. Resuscitation. 2016;107:31–7.CrossRefPubMed
34.
Laina A, Karlis G, Liakos A, et al. Amiodarone and cardiac arrest: Systematic review and meta-analysis. Int J Cardiol. 2016;221:780–8.CrossRefPubMed
35.
Sugiyama K, Kashiura M, Hamabe Y. Amiodarone and lidocaine for shock refractory ventricular fibrillation or ventricular tachycardia in out-of-hospital cardiac arrest: are they really effective? J Thorac Dis. 2016;8:E791–3.CrossRefPubMedPubMedCentral
36.
Ho AF, Ong ME. Antiarrhythmic drugs in out-of-hospital cardiac arrest-what does the Amiodarone, Lidocaine, or Placebo Study tell us? J Thorac Dis. 2016;8:E604–6.CrossRefPubMedPubMedCentral
37.
Joglar JA, Page RL. Out-of-hospital cardiac arrest – are drugs ever the answer? N Engl J Med. 2016;374:1781–2.CrossRefPubMed
38.
Kudenchuk PJ, Daya M, Dorian P, Resuscitation Outcomes Consortium I. Amiodarone, lidocaine, or placebo in out-of-hospital cardiac arrest. N Engl J Med. 2016;375:802–3.PubMed
39.
Weisfeldt ML, Becker LB. Resuscitation after cardiac arrest: a 3-phase time-sensitive model. JAMA. 2002;288:3035–8.CrossRefPubMed
Metadata
Title
Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation
Authors
Takashi Tagami
Hideo Yasunaga
Hiroyuki Yokota
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Critical Care / Issue 1/2017
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/s13054-017-1639-8

Other articles of this Issue 1/2017

Critical Care 1/2017 Go to the issue

Research

Intestinal T lymphocyte homing is associated with gastric emptying and epithelial barrier function in critically ill: a prospective observational study

Research

The association of time and medications with changes in bone mineral density in the 2 years after critical illness

Research

A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients

Research

Timing of renal replacement therapy and long-term risk of chronic kidney disease and death in intensive care patients with acute kidney injury

Research

Circulating levels of soluble Fas (sCD95) are associated with risk for development of a nonresolving acute kidney injury subphenotype

Research

Low-dose immunoglobulin G is not associated with mortality in patients with sepsis and septic shock